A Phase 1/2 interventional study of Zosuquidar and Daunorubicin in Leukemia, Myeloid, sponsored by Kanisa Pharmaceuticals. Completed. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-01.
Sponsored by Kanisa Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 25th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2005, is one of 4 in phase 1/2, and was the 12th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Kura Oncology, Inc. · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
Richard Stone, MD · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
By country, each count listing its studies:
Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 55 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 23 · Phase 3 14 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 111 across the 48 interventional studies. Of the 29 that completed or were terminated, 11 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
Kanisa Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Kanisa Pharmaceuticals has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
4 of the studies testing daunorubicin in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07561892Fujian Medical University Union HospitalStudy of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). | 2026-12-31 |
| NCT04801797Massachusetts General HospitalVenetoclax + Azacitidine vs. Induction Chemotherapy in AML | 2027-01-01 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
| NCT05554406National Cancer Institute (NCI)Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.
Purpose:
Phase I:
To Evaluate the safety of different doses of zosuquidar.
Phase II:
This study is designed to study the safety and effectiveness of zosuquidar when given with daunorubicin and cytarabine in newly diagnosed AML patients.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
This study's planned enrollment of 100 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →Kanisa Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For Phase II:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daunorubicin · Cytarabine
Kanisa Pharmaceuticals